World Congress on Radiology and Oncology(10 Plenary Forums - 1Event) October 19-20, 2017 New York, USA

Biography:

Dr. Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Inventor of the anticancer preparation on basis of celandine alkaloids “NSC-631570”. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmasists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.

Abstract:

I n a controlled clinical study conducted at the University Grodno (Grodno, Belarus), after the therapy with NSC 631570 the hardening of the tumor, a slight increase in the tumor size (5-10%) and proliferation of connective tissues were observed. The T4/T8 lymphocytes ratio increased by 30%. The tumours appeared harder and slightly enlarged after NSC 631570 therapy, and were easier to detect by ultrasound or radiological examination. Metastatic lymph nodes were also hardened and sclerotic (fibrous). Tumours and metastatic lymph nodes were clearly demarcated from healthy tissue and therefore easier to remove. Complications such as prolonged lymphorrhoea (leakage of lymph onto the skin surface), skin necrosis (death of skin tissue), suppuration of the wound, and pneumonia, all occurred in patients from the two NSC 631570 groups at only half the rate that they appeared in patients from the control group. Based on the results of this study the scientists from Grodno recommended the use of NSC 631570, at the higher dosage, in all breast cancer operations (54, 68-70, 114). Other parameters were also evaluated, e.g. hormones (T3, T4, cortisol, progesterone, estradiol, prolactin; 71), immune values (lymphocytes, immune globulins, complement, phagocytic activity; 72), morphologic and cytochemical changes (73, 110), amino acids and their derivates in plasma (74, 109) and in the tumor tissue (75). In a series of articles the researchers have studied the effect of NSC 631570 on various parameters in breast cancer patients (157-160). Best results were achieved with higher dosage of NSC 631570. Almost every patient noted the improvement of the general well-being, sleep and appetite. During the surgery, the tumors as well as involved lymph nodes were presented sclerotic and well demarcated from the surrounding tissue. This alleviated the surgical removal of the tumor considerably (158). In the tumor tissue, increased concentration of the amino acid proline was revealed indicating augmented production of connective tissue that demarcates the tumor from surrounding tissue (159). NSC 631570 improved also the amino acid balance of patients (160). A recent in vitro study with murine and human cancer cell lines confirmed these good results in the treatment of breast cancer were not accidental. The researches from Emory University (Atlanta, Georgia, USA) and Kennesaw State University (Kennesaw, Georgia, USA) concluded: “The anticancer drug Ukrain experts its cytotoxic effects on both mouse and human breast cancer cell lines in a dose and time dependent manner. Weeks following Ukraine treatment, cells maintained a reduced capacity to proliferate. Our data suggest that Ukraine could be effective as an anticancer drug for breast cancer due to its short term and long term inhibitory effects on tumor cell viability and proliferation” (268). This work was supported by RO1 CA-138993 and the NSF Award #0450303 Subaward #1- 66-606-63. The National Science Foundation (NSF) is an independent federal agency created by the US Congress in 1950 “to promote the progress of science, to advance the national health, prosperity, and welfare, to secure the national defense…” With an annual budget about $6,9 billion (FY 2010), NSF is the funding source for approximately 20 percent of all federally supported basic research conducted by America`s colleges and universities..